Long-term outcomes of drug-coated balloon treatment of calcified coronary artery lesions: a multicenter, retrospective, propensity matching study

被引:1
|
作者
Shan, Yingguang [1 ]
Lu, Wenjie [1 ]
Han, Zhanying [1 ]
Pan, Sancong [2 ]
Li, Xiangbing [2 ]
Wang, Xi [1 ]
Pan, Liang [1 ]
Wang, Xule [1 ]
Zheng, Xiaolin [1 ]
Li, Ran [1 ]
Zhou, Yanjun [1 ]
Qin, Peng [3 ]
Shi, Qiangwei [1 ]
Zhou, Shuai [1 ]
Zhang, Wencai [1 ]
Guo, Sen [1 ]
Qiu, Jing [1 ]
Zhang, Peisheng [4 ]
Qin, Xiaofei [1 ]
Sun, Guoju [1 ]
Qin, Zhongsheng [2 ]
Huang, Zhenwen [1 ]
Qiu, Chunguang [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Zhengzhou, Peoples R China
[2] Jincheng Peoples Hosp, Dept Cardiovasc Med, Jincheng, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Geriatr Cardiol, Zhengzhou, Peoples R China
[4] Zhengzhou Univ, Affiliated Hosp 1, Dept Cardiol, Zhengzhou, Peoples R China
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2023年 / 10卷
关键词
coronary artery calcification; drug-coated balloon; de novo; PCI; propensity matching; POOLED ANALYSIS; ELUTING STENTS; INTERVENTION; CALCIFICATION;
D O I
10.3389/fcvm.2023.1122290
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundCoronary artery calcification (CAC) is associated with high rates of restenosis and adverse clinical events after percutaneous coronary intervention (PCI) with drug-eluting stents (DES).ObjectivesThe aim of this study was to evaluate the long-term clinical outcomes of drug-coated balloon (DCB)-only treatment for de novo lesions with and without CAC.MethodsPatients with de novo coronary disease treated with the DCB-only strategy were retrospectively enrolled from three centers and categorized into a CAC group and a non-CAC group. The primary endpoint was the target lesion failure (TLF) rate during the 3-year follow-up. Secondary endpoints included the occurrence of major adverse cardiac events (MACEs), target lesion revascularization (TLR), cardiac death, myocardial infarction (MI) and any revascularization. Propensity score matching (PSM) was conducted to assemble a cohort of patients with similar baseline characteristics.ResultsA total of 1,263 patients with 1,392 lesions were included, and 243 patients were included in each group after PSM. Compared with the non-CAC group, the incidence rates of TLF (9.52% vs. 4.94%, odds ratio [OR]: 2.080; 95% confidence interval [CI]: 1.083-3.998, P = 0.034) and TLR (7.41% vs. 2.88%, OR: 2.642; 95% CI: 1.206-5.787, P = 0.020) in the CAC group were higher. The incidence rates of MACE (12.35% vs. 7.82%, OR: 1.665; 95% CI: 0.951-2.916, P = 0.079), cardiac death (2.06% vs. 2.06%, OR: 0.995; 95% CI: 0.288-3.436, P = 0.993), MI (1.23% vs. 0.82%, OR: 2.505; 95% CI: 0.261-8.689, P = 0.652) and any revascularization (12.76% vs. 9.67%, OR: 1.256; 95% CI: 0.747-2.111, P = 0.738) were similar between groups.ConclusionsCAC increased the incidence of TLF and TLR without a substantial increase in the risk of MACE, cardiac death, MI, or any revascularization in patients treated with DCB-only angioplasty during the 3-year follow-up.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Short-term outcomes from drug-coated balloon for coronary de novo lesions in large vessels
    Lu, Wenjie
    Zhu, Yongjian
    Han, Zhanying
    Sun, Guoju
    Qin, Xiaofei
    Wang, Zhengbin
    Liu, Guanghui
    Wang, Xi
    Wang, Xule
    Pan, Liang
    Qiu, Chunguang
    JOURNAL OF CARDIOLOGY, 2019, 73 (1-2) : 151 - 155
  • [32] One-year outcomes of drug-coated balloon treatment for long femoropopliteal lesions: a multicentre cohort and real-world study
    Yu, Xiaoxi
    Zhang, Xin
    Lai, Zhichao
    Shao, Jiang
    Zeng, Rong
    Ye, Wei
    Chen, Yuexin
    Zhang, Bihui
    Ma, Bo
    Cao, Wenteng
    Liu, Xiaolong
    Yuan, Jinghui
    Zheng, Yuehong
    Yang, Min
    Ye, Zhidong
    Liu, Bao
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [33] Clinical outcomes of drug-coated balloon for treatment of de novo coronary artery disease with and without diabetes
    Zhang, Zhaoqian
    Tan, Qiang
    Zhang, Jiarui
    Wang, Xinhui
    Wang, Qian
    SAUDI MEDICAL JOURNAL, 2022, 43 (12) : 1347 - 1353
  • [34] Coronary Artery Dissection in Drug-Coated Balloon Angioplasty: Incidence, Predictors, and Clinical Outcomes
    Gitto, Mauro
    Leone, Pier Pasquale
    Gioia, Francesco
    Chiarito, Mauro
    Latini, Alessia
    Tartaglia, Francesco
    Kilic, Ismail Dogu
    Rossi, Marco Luciano
    Regazzoli, Damiano
    Gasparini, Gabriele
    Cozzi, Ottavia
    Sticchi, Alessandro
    Condorelli, Gianluigi
    Reimers, Bernhard
    Stefanini, Giulio
    Mangieri, Antonio
    Colombo, Antonio
    AMERICAN JOURNAL OF CARDIOLOGY, 2025, 239 : 28 - 35
  • [35] Feasibility and Safety of Drug-Coated Balloon for Treatment of De Novo Coronary Artery Lesions in Large Vessel Disease: A Large-Scale Multicenter Prospective Study
    Gao, Guofeng
    Wang, Hao-Yu
    Song, Yanjun
    Yin, Dong
    Feng, Lei
    Wang, Hao
    Xu, Han
    Zhao, Zhiyong
    Yang, Min
    Lu, Yingming
    Ji, Zheng
    Zhu, Chenggang
    Dou, Kefei
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2023, 24 (10)
  • [36] A retrospective study of drug-coated balloon angioplasty for vertebral artery origin stenosis
    Kai Zhao
    Peng Yan
    Xiang Wang
    Yuanyuan Zhao
    Shan Li
    Yuan Xue
    Xiaohui Liu
    Jifeng Li
    Qinjian Sun
    Neuroradiology, 2022, 64 : 1617 - 1625
  • [37] Efficacy and risks of drug-coated balloon treatment for coronary artery disease: A meta-analysis
    Bai, Xinghua
    Shen, Chaofeng
    Zhang, Weizong
    Yu, Tao
    Jiang, Jun
    HELIYON, 2023, 9 (11)
  • [38] Drug-coated balloon combined with drug-eluting stent for the treatment of coronary bifurcation lesions: insights from the HYPER study
    Pellegrini, Dario
    Donahue, Michael
    Regazzoli, Damiano
    Tedeschi, Delio
    Loffi, Marco
    Pellicano, Mariano
    De Blasio, Giuseppe
    Tespili, Maurizio
    Guagliumi, Giulio
    Ielasi, Alfonso
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25 : C79 - C83
  • [39] Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: the SPARTAN DCB study
    Ioannis Merinopoulos
    Tharusha Gunawardena
    Upul Wickramarachchi
    Paul Richardson
    Clint Maart
    Sulfi Sreekumar
    Chris Sawh
    Trevor Wistow
    Toomas Sarev
    Alisdair Ryding
    Tim Gilbert
    Aris Perperoglou
    Vassilios S. Vassiliou
    Simon C. Eccleshall
    Clinical Research in Cardiology, 2021, 110 : 220 - 227
  • [40] A Multicenter Randomized Trial Assessing ZENFlow Carrier-Free Drug-Coated Balloon for the Treatment of Femoropopliteal Artery Lesions
    Ni, Leng
    Ye, Wei
    Zhang, Lan
    Jin, Xing
    Shu, Chang
    Jiang, Jin-Song
    Yang, Mu
    Wu, Dan-Ming
    Li, Ming
    Yu, Guan-Feng
    Yang, Jun
    Huang, Jian-Hua
    Wang, Xiao-Bai
    Li, Xiao-Qiang
    Jiang, Wei-Liang
    Wu, Zhi-Qun
    Liu, Chang-Wei
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9